FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310125628> ?p ?o ?g. }

• W4310125628 endingPage "10952" @default.
• W4310125628 startingPage "10951" @default.
• W4310125628 abstract "Background: Increased use of oral anticancer agents (OAA) has empowered adults with chronic lymphocytic leukemia (CLL) to manage their therapy independently. However, comorbid chronic disease is common among patients with CLL, and initiating OAA therapy increases the treatment burden on adults with both cancer and multiple chronic conditions (MCC). The objective of this research was to examine adherence to OAAs in adult patients with CLL newly initiating OAA treatment and assess the extent to which such initiation impacted adherence to medications for existing comorbid chronic conditions. Methods: This retrospective cohort study used commercial (MarketScan) and Medicare (20% sample) claims data for 2013-2018 to assess medication use in adults with CLL. To be included, patients must have been: 1) at least 18 years old; 2) diagnosed with and had 2+ claims for an OAA indicated for either CLL; 3) continuously enrolled 12 months before and after OAA initiation; and 4) treated for (2+ fills before and after OAA initiation) at least 2 select chronic conditions (diabetes, hypertension, or hyperlipidemia plus at least 1 other chronic condition). Proportion of days covered (PDC) determined medication adherence for all included medication classes and was compared for the 12 months before and after OAA initiation by Wilcoxon signed-rank tests and McNemar's tests. Multivariable logistic regression identified predictors of OAA adherence in the first year of therapy while controlling for available demographic and clinical characteristics. Difference-in-differences models assessed the change in adherence to select comorbid chronic disease medications before and after OAA initiation. Results: The final analysis included 246 (commercial) and 805 (Medicare) adults with CLL and MCC. Mean OAA adherence in the first year of therapy was 79.8% (SD: 21.1) and 74.7% (SD: 24.9) for commercial and Medicare patients, respectively, translating to 68.3% (commercial) and 59.1% (Medicare) being adherent (PDC>80%). An increase in comorbidity burden was associated with a lower odds of OAA adherence and was the sole significant predictor in the Medicare models: OR=0.87 (95% CI: 0.82-0.92) for Medicare members and OR=0.83 (95% CI: 0.73-0.95) with commercial coverage. Among adults with commercial coverage, the odds of OAA adherence were lower for residents of the South (OR=0.39; 95% CI: 0.16-0.94; compared to the Northeast), but higher among those using a greater number of medications overall (OR=1.08; 95% CI: 1.01-1.16). No significant changes in mean adherence to MCC medications were observed, irrespective of payer, when comparing values before and after OAA initiation (Figure Panel A), including when accounting for OAA adherence in the first year of therapy. However, compared to the first 6 months post-OAA initiation, mean PDCs in the second half of the year noticeably declined, irrespective of comorbidity or payer cohort, with PDC declines ranging from 3.0 (antihypertensives, Medicare) to 11.1 (antihypertensives, Medicare) percentage points (Figure Panel B). Conclusion: Using nationally representative claims data, this study found that initial OAA adherence was generally good among adults with CLL, with a majority of patients reaching accepted thresholds of adequate anticancer medication use. Additionally, few differences in adherence were observed in multivariable analyses using a range of patients’ characteristics, irrespective of payer or cancer type. Importantly, limited evidence of changes in adherence to oral antidiabetic, antihypertensive, or lipid-lowering agents were found in the first year following OAA initiation. However, these findings do not negate the need for careful monitoring of medication use in these populations over the course of time as some eventual declines in comorbid chronic disease medication adherence were observed. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310125628 created "2022-11-30" @default.
• W4310125628 creator A5012676554 @default.
• W4310125628 creator A5032953928 @default.
• W4310125628 creator A5037221906 @default.
• W4310125628 creator A5040283829 @default.
• W4310125628 creator A5043419293 @default.
• W4310125628 creator A5055741970 @default.
• W4310125628 creator A5078744558 @default.
• W4310125628 creator A5082024441 @default.
• W4310125628 date "2022-11-15" @default.
• W4310125628 modified "2023-09-26" @default.
• W4310125628 title "Impact of Initiating Oral Anticancer Agent Therapy for Chronic Lymphocytic Leukemia Among Adults with Multiple Chronic Conditions" @default.
• W4310125628 doi "https://doi.org/10.1182/blood-2022-167534" @default.
• W4310125628 hasPublicationYear "2022" @default.
• W4310125628 type Work @default.
• W4310125628 citedByCount "0" @default.
• W4310125628 crossrefType "journal-article" @default.
• W4310125628 hasAuthorship W4310125628A5012676554 @default.
• W4310125628 hasAuthorship W4310125628A5032953928 @default.
• W4310125628 hasAuthorship W4310125628A5037221906 @default.
• W4310125628 hasAuthorship W4310125628A5040283829 @default.
• W4310125628 hasAuthorship W4310125628A5043419293 @default.
• W4310125628 hasAuthorship W4310125628A5055741970 @default.
• W4310125628 hasAuthorship W4310125628A5078744558 @default.
• W4310125628 hasAuthorship W4310125628A5082024441 @default.
• W4310125628 hasBestOaLocation W43101256281 @default.
• W4310125628 hasConcept C126322002 @default.
• W4310125628 hasConcept C143998085 @default.
• W4310125628 hasConcept C203014093 @default.
• W4310125628 hasConcept C2777938653 @default.
• W4310125628 hasConcept C2778461978 @default.
• W4310125628 hasConcept C2779878957 @default.
• W4310125628 hasConcept C2781442060 @default.
• W4310125628 hasConcept C71924100 @default.
• W4310125628 hasConceptScore W4310125628C126322002 @default.
• W4310125628 hasConceptScore W4310125628C143998085 @default.
• W4310125628 hasConceptScore W4310125628C203014093 @default.
• W4310125628 hasConceptScore W4310125628C2777938653 @default.
• W4310125628 hasConceptScore W4310125628C2778461978 @default.
• W4310125628 hasConceptScore W4310125628C2779878957 @default.
• W4310125628 hasConceptScore W4310125628C2781442060 @default.
• W4310125628 hasConceptScore W4310125628C71924100 @default.
• W4310125628 hasIssue "Supplement 1" @default.
• W4310125628 hasLocation W43101256281 @default.
• W4310125628 hasOpenAccess W4310125628 @default.
• W4310125628 hasPrimaryLocation W43101256281 @default.
• W4310125628 hasRelatedWork W2100707039 @default.
• W4310125628 hasRelatedWork W2125722196 @default.
• W4310125628 hasRelatedWork W2297783661 @default.
• W4310125628 hasRelatedWork W2519856255 @default.
• W4310125628 hasRelatedWork W2523010309 @default.
• W4310125628 hasRelatedWork W2565793404 @default.
• W4310125628 hasRelatedWork W2593690797 @default.
• W4310125628 hasRelatedWork W2963940374 @default.
• W4310125628 hasRelatedWork W4256251739 @default.
• W4310125628 hasRelatedWork W4283518388 @default.
• W4310125628 hasVolume "140" @default.
• W4310125628 isParatext "false" @default.
• W4310125628 isRetracted "false" @default.
• W4310125628 workType "article" @default.